Advertisement

Transurethral Resection of Bladder Tumors: Improving Quality Through New Techniques and Technologies

  • Daniel Zainfeld
  • Siamak DaneshmandEmail author
Minimally Invasive Surgery (T Guzzo, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Minimally Invasive Surgery

Abstract

Purpose of Review

Cystoscopy with transurethral resection of bladder tumors (TURBT) is essential in the diagnosis of bladder cancer as well as the management of non-muscle-invasive disease yet remains a comparatively imprecise procedure secondary to variability among patients, tumors, and surgeons alike. We will review evolving technologies and techniques used to enhance safety and efficacy of TURBT performance and education in the management of bladder cancer.

Recent Findings

Though a generally safe procedure, efficacy of TURBT in terms of complete tumor excision, appropriate pathologic diagnosis, and absence of complications can vary significantly with direct impact on patient outcomes. Application of new techniques including bipolar electrocautery and photodynamic enhancement continues to shape endoscopic management of bladder cancer and improve safety, tumor excision rates, and downstream outcomes.

Summary

High-quality bladder tumor resection is essential for effective bladder cancer management. Technologies such as bipolar electrocautery and photodynamic visualization improve safety and tumor eradication. Improved education and surgical technique will further standardize high-level outcomes for patients undergoing TURBT.

Keywords

Bladder cancer Monopolar Bipolar Transurethral resection Blue light 

Notes

Compliance with Ethical Standards

Conflict of Interest

Daniel Zainfeld and Siamak Daneshmand declare no potential conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.PubMedGoogle Scholar
  2. 2.
    Beer E. Landmark article May 28, 1910: removal of neoplasms of the urinary bladder. By Edwin Beer. JAMA. 1983;250(10):1324–5.PubMedGoogle Scholar
  3. 3.
    Cohen RA, Brown RS. Clinical practice. Microscopic hematuria. N Engl J Med. 2003;348(23):2330–8.PubMedGoogle Scholar
  4. 4.
    National Collaborating Centre for Cancer (UK). Bladder Cancer: Diagnosis and Management [Internet]. London: National Institute for Health and Care Excellence (UK); 2015 [cited 2016 Oct 27]. (National Institute for Health and Clinical Excellence: Guidance). Available from: http://www.ncbi.nlm.nih.gov/books/NBK305022/
  5. 5.
    Professionals S-O. Non-muscle-invasive Bladder Cancer [Internet]. Uroweb. 2015 [cited 2016 Oct 27]. Available from: https://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/
  6. 6.
    Non-Muscle Invasive Bladder Cancer: American Urological Association [Internet]. [cited 2016]. Available from: http://www.auanet.org/education/guidelines/non-muscle-invasive-bladder-cancer.cfm
  7. 7.
    Tan WS, Rodney S, Lamb B, Feneley M, Kelly J. Management of non-muscle invasive bladder cancer: a comprehensive analysis of guidelines from the United States, Europe and Asia. Cancer Treat Rev. 2016;47:22–31.PubMedGoogle Scholar
  8. 8.
    Sylvester RJ, van der Meijden APM, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3):466. -465-477PubMedGoogle Scholar
  9. 9.
    Svatek RS, Hollenbeck BK, Holmäng S, Lee R, Kim SP, Stenzl A, et al. The economics of bladder cancer: costs and considerations of caring for this disease. Eur Urol. 2014;66(2):253–62.PubMedGoogle Scholar
  10. 10.
    • Matulewicz RS, Sharma V, McGuire BB, Oberlin DT, Perry KT, Nadler RB. The effect of surgical duration of transurethral resection of bladder tumors on postoperative complications: an analysis of ACS NSQIP data. Urol Oncol. 2015;33(8):338.e19–24. Evaluation of impact of surgical duration on complications from TURBT in ACS NSQIP database demonstrating increased complications with greater operative times. Google Scholar
  11. 11.
    Hollenbeck BK, Miller DC, Taub D, Dunn RL, Khuri SF, Henderson WG, et al. Risk factors for adverse outcomes after transurethral resection of bladder tumors. Cancer. 2006;106(7):1527–35.PubMedGoogle Scholar
  12. 12.
    Rassweiler J, Teber D, Kuntz R, Hofmann R. Complications of transurethral resection of the prostate (TURP)—incidence, management, and prevention. Eur Urol. 2006;50(5):969–79. discussion 980.PubMedGoogle Scholar
  13. 13.
    Hawary A, Mukhtar K, Sinclair A, Pearce I. Transurethral resection of the prostate syndrome: almost gone but not forgotten. J Endourol. 2009;23(12):2013–20.PubMedGoogle Scholar
  14. 14.
    Singhania P, Nandini D, Sarita F, Hemant P, Hemalata I. Transurethral resection of prostate: a comparison of standard monopolar versus bipolar saline resection. Int Braz J Urol Off J Braz Soc Urol. 2010;36(2):183–9.Google Scholar
  15. 15.
    Tang Y, Li J, Pu C, Bai Y, Yuan H, Wei Q, et al. Bipolar transurethral resection versus monopolar transurethral resection for benign prostatic hypertrophy: a systematic review and meta-analysis. J Endourol. 2014;28(9):1107–14.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Puppo P, Bertolotto F, Introini C, Germinale F, Timossi L, Naselli A. Bipolar transurethral resection in saline (TURis): outcome and complication rates after the first 1000 cases. J Endourol. 2009;23(7):1145–9.PubMedGoogle Scholar
  17. 17.
    Gupta NP, Saini AK, Dogra PN, Seth A, Kumar R. Bipolar energy for transurethral resection of bladder tumours at low-power settings: initial experience. BJU Int. 2011;108(4):553–6.PubMedGoogle Scholar
  18. 18.
    Xishuang S, Deyong Y, Xiangyu C, Tao J, Quanlin L, Hongwei G, et al. Comparing the safety and efficiency of conventional monopolar, plasmakinetic, and holmium laser transurethral resection of primary non-muscle invasive bladder cancer. J Endourol. 2010;24(1):69–73.PubMedGoogle Scholar
  19. 19.
    Mashni J, Godoy G, Haarer C, Dalbagni G, Reuter VE, Al-Ahmadie H, et al. Prospective evaluation of plasma kinetic bipolar resection of bladder cancer: comparison to monopolar resection and pathologic findings. Int Urol Nephrol. 2014;46(9):1699–705.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Del Rosso A, Pace G, Masciovecchio S, Saldutto P, Galatioto GP, Vicentini C. Plasmakinetic bipolar versus monopolar transurethral resection of non-muscle invasive bladder cancer: a single center randomized controlled trial. Int J Urol Off J Jpn Urol Assoc. 2013;20(4):399–403.Google Scholar
  21. 21.
    • Venkatramani V, Panda A, Manojkumar R, Kekre NS. Monopolar versus bipolar transurethral resection of bladder tumors: a single center, parallel arm, randomized, controlled trial. J Urol. 2014;191(6):1703–7. Randomized trail evaluating use of monopolar versus bipolar energy for TURBTs. Similar outcomes between the two arms though decreased frequency of severe cautery artifact in the bipolar arm. Google Scholar
  22. 22.
    Sugihara T, Yasunaga H, Horiguchi H, Matsui H, Nishimatsu H, Nakagawa T, et al. Comparison of perioperative outcomes including severe bladder injury between monopolar and bipolar transurethral resection of bladder tumors: a population based comparison. J Urol. 2014;192(5):1355–9.PubMedGoogle Scholar
  23. 23.
    Zhao C, Tang K, Yang H, Xia D, Chen Z. Bipolar versus monopolar transurethral resection of nonmuscle-invasive bladder cancer: a meta-analysis. J Endourol. 2016;30(1):5–12.PubMedGoogle Scholar
  24. 24.
    Lagerveld BW, Koot RAC, Smits GAHJ. Thermal artifacts in bladder tumors following loop endoresection: electrovaporization v electrocauterization. J Endourol. 2004;18(6):583–6.PubMedGoogle Scholar
  25. 25.
    Wang DS, Bird VG, Leonard VY, Plumb SJ, Konety B, Williams RD, et al. Use of bipolar energy for transurethral resection of bladder tumors: pathologic considerations. J Endourol Endourol Soc. 2004;18(6):578–82.Google Scholar
  26. 26.
    Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Compérat EM, et al. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol. 2016.Google Scholar
  27. 27.
    Gendy R, Delprado W, Brenner P, Brooks A, Coombes G, Cozzi P, et al. Repeat transurethral resection for non-muscle-invasive bladder cancer: a contemporary series. BJU Int. 2016;117(Suppl 4):54–9.PubMedGoogle Scholar
  28. 28.
    Brausi M, Collette L, Kurth K, van der Meijden AP, Oosterlinck W, Witjes JA, et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol. 2002;41(5):523–31.PubMedGoogle Scholar
  29. 29.
    Herr HW. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy. J Urol. 2005;174(6):2134–7.PubMedGoogle Scholar
  30. 30.
    Schwaibold HE, Sivalingam S, May F, Hartung R. The value of a second transurethral resection for T1 bladder cancer. BJU Int. 2006;97(6):1199–201.PubMedGoogle Scholar
  31. 31.
    Dwivedi US, Kumar A, Das SK, Trivedi S, Kumar M, Sunder S, et al. Relook TURBT in superficial bladder cancer: its importance and its correlation with the tumor ploidy. Urol Oncol. 2009;27(5):514–9.PubMedGoogle Scholar
  32. 32.
    Herr HW. Role of repeat resection in non-muscle-invasive bladder cancer. J Natl Compr Cancer Netw JNCCN. 2015;13(8):1041–6.Google Scholar
  33. 33.
    Divrik RT, Sahin AF, Yildirim U, Altok M, Zorlu F. Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial. Eur Urol. 2010;58(2):185–90.PubMedGoogle Scholar
  34. 34.
    Adiyat KT, Katkoori D, Soloway CT, De los Santos R, Manoharan M, Soloway MS. “complete transurethral resection of bladder tumor”: are the guidelines being followed? Urology. 2010;75(2):365–7.PubMedGoogle Scholar
  35. 35.
    Daneshmand S, Schuckman AK, Bochner BH, Cookson MS, Downs TM, Gomella LG, et al. Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA. Nat Rev Urol. 2014;11(10):589–96.PubMedGoogle Scholar
  36. 36.
    Kołodziej A, Krajewski W, Matuszewski M, Tupikowski K. Review of current optical diagnostic techniques for non-muscle-invasive bladder cancer. Cent Eur J Urol. 2016;69(2):150–6.Google Scholar
  37. 37.
    Fradet Y, Grossman HB, Gomella L, Lerner S, Cookson M, Albala D, et al. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol. 2007;178(1):68–73. discussion 73.PubMedGoogle Scholar
  38. 38.
    Stenzl A, Burger M, Fradet Y, Mynderse LA, Soloway MS, Witjes JA, et al. Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol. 2010;184(5):1907–13.PubMedPubMedCentralGoogle Scholar
  39. 39.
    •• Grossman HB, Stenzl A, Fradet Y, Mynderse LA, Kriegmair M, Witjes JA, et al. Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. J Urol. 2012;188(1):58–62. Long-term outcomes of randomized study demonstrating impact of improved tumor resection enhanced by photodynamic diagnosis.PubMedPubMedCentralGoogle Scholar
  40. 40.
    Rink M, Babjuk M, Catto JWF, Jichlinski P, Shariat SF, Stenzl A, et al. Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature. Eur Urol. 2013;64(4):624–38.PubMedGoogle Scholar
  41. 41.
    • Burger M, Grossman HB, Droller M, Schmidbauer J, Hermann G, Drăgoescu O, et al. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol. 2013;64(5):846–54. Meta-analysis of studies evaluating outcomes with addition of blue light cystoscopy in completion of TURBT.PubMedGoogle Scholar
  42. 42.
    Witjes JA, Babjuk M, Gontero P, Jacqmin D, Karl A, Kruck S, et al. Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations. Eur Urol. 2014;66(5):863–71.PubMedGoogle Scholar
  43. 43.
    Naselli A, Introini C, Bertolotto F, Spina B, Puppo P. Feasibility of transurethral resection of bladder lesion performed entirely by means of narrow-band imaging. J Endourol. 2010;24(7):1131–4.PubMedGoogle Scholar
  44. 44.
    Naito S, Algaba F, Babjuk M, Bryan RT, Sun Y-H, Valiquette L, et al. The clinical research Office of the Endourological Society (CROES) multicentre randomised trial of narrow band imaging-assisted transurethral resection of bladder tumour (TURBT) versus conventional white light imaging-assisted TURBT in primary non-muscle-invasive bladder cancer patients: trial protocol and 1-year results. Eur Urol. 2016;70(3):506–15.PubMedGoogle Scholar
  45. 45.
    Kausch I, Sommerauer M, Montorsi F, Stenzl A, Jacqmin D, Jichlinski P, et al. Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. Eur Urol. 2010;57(4):595–606.PubMedGoogle Scholar
  46. 46.
    • Bos D, Allard CB, Dason S, Ruzhynsky V, Kapoor A, Shayegan B. Impact of resident involvement in endoscopic bladder cancer surgery on pathological outcomes. Scand J Urol. 2016;50(3):234–8. Recent retrospective review demonstrating variability in clinical outcomes from TURBT. Indicates surgeon experience relevant among other clinical factors.PubMedGoogle Scholar
  47. 47.
    Huang J, Fu J, Zhan H, Xie K, Liu B, Yang F, et al. Analysis of the absence of the detrusor muscle in initial transurethral resected specimens and the presence of residual tumor tissue. Urol Int. 2012;89(3):319–25.PubMedGoogle Scholar
  48. 48.
    Mariappan P, Zachou A, Grigor KM, Edinburgh Uro-Oncology Group. Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience. Eur Urol. 2010;57(5):843–9.PubMedGoogle Scholar
  49. 49.
    Shoshany O, Mano R, Margel D, Baniel J, Yossepowitch O. Presence of detrusor muscle in bladder tumor specimens—predictors and effect on outcome as a measure of resection quality. Urol Oncol. 2014;32(1):40.e17–22.Google Scholar
  50. 50.
    Kruck S, Bedke J, Hennenlotter J, Amend B, Merseburger A, Stenzl A, et al. Virtual bladder tumor transurethral resection: an objective evaluation tool to overcome learning curves with and without photodynamic diagnostics. Urol Int. 2011;87(2):138–42.PubMedGoogle Scholar
  51. 51.
    Aydin A, Shafi AMA, Shamim Khan M, Dasgupta P, Ahmed K. Current status of simulation and training models in urological surgery: a systematic review. J Urol. 2016;196(2):312–20.PubMedGoogle Scholar
  52. 52.
    de Vries AH, van Genugten HGJ, Hendrikx AJM, Koldewijn EL, Schout BMA, Tjiam IM, et al. The Simbla TURBT simulator in urological residency training: from needs analysis to validation. J Endourol. 2015;30(5):580–7.Google Scholar
  53. 53.
    • Bazargani S, Djaladat H, Schuckman AK, Hugen C, Daneshmand S. Blue light cystoscopy with Cysview: The USC experience. Video publication demonstrating both application of blue light cystoscopy and as “intermittent resection technique.” Google Scholar
  54. 54.
    Liem EI, de Reijke TM. Can we improve transurethral resection of the bladder tumour for nonmuscle invasive bladder cancer? Curr Opin Urol. 2016.Google Scholar
  55. 55.
    Wu Y-P, Lin T-T, Chen S-H, Xu N, Wei Y, Huang J-B, et al. Comparison of the efficacy and feasibility of en bloc transurethral resection of bladder tumor versus conventional transurethral resection of bladder tumor: a meta-analysis. Medicine (Baltimore). 2016;95(45):e5372.Google Scholar
  56. 56.
    Kramer MW, Rassweiler JJ, Klein J, Martov A, Baykov N, Lusuardi L, et al. En bloc resection of urothelium carcinoma of the bladder (EBRUC): a European multicenter study to compare safety, efficacy, and outcome of laser and electrical en bloc transurethral resection of bladder tumor. World J Urol. 2015;33(12):1937–43.PubMedGoogle Scholar
  57. 57.
    Hurle R, Lazzeri M, Colombo P, Buffi N, Morenghi E, Peschechera R, et al. “en bloc” resection of nonmuscle invasive bladder cancer: a prospective single-center study. Urology. 2016;90:126–30.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  1. 1.USC Norris Comprehensive Cancer CenterLos AngelesUSA

Personalised recommendations